Akt: A Potential Drug Target for Metabolic Syndrome

作者：Runyu Miao, Xinyi Fang, Jiahua Wei, Haoran Wu, Xinmiao Wang, Jiaxing Tian · 发表于：Frontiers in Physiology · 年份：2022 · DOI：10.3389/fphys.2022.822333 · 被引用次数：79 · 研究领域：Metabolism, Diabetes, and Cancer、PI3K/AKT/mTOR signaling in cancer、Diet, Metabolism, and Disease

The serine/threonine kinase Akt, also known as protein kinase B (PKB), is one of the key factors regulating glucose and lipid energy metabolism, and is the core focus of current research on diabetes and metabolic diseases. Akt is mostly expressed in key metabolism-related organs and it is activated in response to various stimuli, including cell stress, cell movement, and various hormones and drugs that affect cell metabolism. Genetic and pharmacological studies have shown that Akt is necessary to maintain the steady state of glucose and lipid metabolism and a variety of cellular responses. Existing evidence shows that metabolic syndrome is related to insulin resistance and lipid metabolism disorders. Based on a large number of studies on Akt-related pathways and reactions, we believe that Akt can be used as a potential drug target to effectively treat metabolic syndrome.